{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:00:26Z","timestamp":1772164826388,"version":"3.50.1"},"reference-count":58,"publisher":"American Association for Cancer Research (AACR)","issue":"11","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013739","name":"Pfizer Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["704970"],"award-info":[{"award-number":["704970"]}],"id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["707213"],"award-info":[{"award-number":["707213"]}],"id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The randomized phase II MA.38 trial estimated the relative progression-free survival (PFS) associated with second-line endocrine therapy plus palbociclib administered on a 100 mg continuous daily dosing (CDD) schedule compared with the standard dose schedule (SDS) of 125 mg (days 1\u201321 of a 28-day cycle). A total of 180 patients were allocated 1:1 to protocol therapy. Molecular profiling was performed on the archival tissue and cell-free DNA (cfDNA) at enrollment, 3 months, and 6 months. The primary analysis for PFS demonstrated a similar outcome for the CDD versus SDS treatment strategy: HR = 0.93 (90% confidence interval, 0.66\u20131.30). Secondary efficacy measures for CDD versus SDS included the following: overall survival, HR = 1.07 (90% confidence interval, 0.67\u20131.69); response rate, 16.1% versus 18.0% (P = 0.66); median duration of response, 4.2 months (range, 2.8\u201313.9 months) versus 5.6 months (range, 2.4\u201313.9 months; P = 0.86); and clinical benefit rate, 53.2% versus 57.3% (P = 0.89). cfDNA profiling of the baseline enrollment sample prior to palbociclib commencement showed low tumor fraction (HR = 2.28; P = 9.9 \u00d7 10\u22126); higher short\/long fragment length ratios (HR = 1.19; P = 0.049) and cfDNA variants in FGFR4 (HR = 3.65; P = 0.012) were prognostic and associated with inferior PFS. Variants in TP53 (HR = 2.48; P = 0.006) and ESR1 (HR = 3.42; P = 0.005) detected at 12 weeks on treatment were also associated with poor PFS. CDD palbociclib 100 mg dosing was not associated with improved efficacy compared with the standard intermittent 125 mg dosing schedule. Additionally, we identified prognostic biomarkers in alignment with prior research and demonstrated the value of cfDNA dynamics, including fragment length ratios and tumor fraction as a measure of treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>A continuous 100 mg dosing schedule of palbociclib was tolerable but not associated with improved efficacy signals versus the standard intermittent 125 mg (days 1\u201321 of a 28-day cycle) schedule. Mutations detected in liquid biopsies and changes in cfDNA dynamics were linked to poor outcomes and may identify patients with treatment-resistant cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0346","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T14:56:03Z","timestamp":1761144963000},"page":"1998-2011","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer"],"prefix":"10.1158","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4201-8930","authenticated-orcid":false,"given":"Anil Abraham","family":"Joy","sequence":"first","affiliation":[{"name":"1Division of Medical Oncology, Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9174-1099","authenticated-orcid":false,"given":"Nicholas","family":"Cheng","sequence":"additional","affiliation":[{"name":"2Computational Biology, Ontario Institute for Cancer Research, Toronto, Canada."},{"name":"3Department of Molecular Genetics, University of Toronto, Toronto, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4111-2757","authenticated-orcid":false,"given":"Karen A.","family":"Gelmon","sequence":"additional","affiliation":[{"name":"4Department of Medical Oncology, Vancouver Centre, BC Cancer, Vancouver, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0982-3592","authenticated-orcid":false,"given":"Mihaela","family":"Mates","sequence":"additional","affiliation":[{"name":"5Department of Oncology, Queen\u2019s University, Kingston Health Sciences Centre, Kingston, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8922-6406","authenticated-orcid":false,"given":"Christine","family":"Desbiens","sequence":"additional","affiliation":[{"name":"6Centre hospitalier universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Qu\u00e9bec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9392-8219","authenticated-orcid":false,"given":"Mark","family":"Clemons","sequence":"additional","affiliation":[{"name":"7Division of Medical Oncology, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4437-1378","authenticated-orcid":false,"given":"Sara","family":"Taylor","sequence":"additional","affiliation":[{"name":"8Medical Oncology, BC Cancer Agency, Kelowna, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6168-320X","authenticated-orcid":false,"given":"Julie","family":"Lemieux","sequence":"additional","affiliation":[{"name":"9Centre hospitalier universitaire de Qu\u00e9bec-Universit\u00e9 Laval, Universit\u00e9 Laval Cancer Research Center, Qu\u00e9bec, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9971-9529","authenticated-orcid":false,"given":"Angela","family":"DeLuca","sequence":"additional","affiliation":[{"name":"10Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5418-6176","authenticated-orcid":false,"given":"Louis","family":"Gasparini","sequence":"additional","affiliation":[{"name":"10Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9996-5771","authenticated-orcid":false,"given":"Ilinca","family":"Lungu","sequence":"additional","affiliation":[{"name":"10Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1325-7417","authenticated-orcid":false,"given":"David","family":"Soave","sequence":"additional","affiliation":[{"name":"2Computational Biology, Ontario Institute for Cancer Research, Toronto, Canada."},{"name":"11Department of Mathematics, Wilfrid Laurier University, Waterloo, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5587-2151","authenticated-orcid":false,"given":"Alex","family":"Fortuna","sequence":"additional","affiliation":[{"name":"12Genome Sequence Informatics, Ontario Institute for Cancer Research, Toronto, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8073-5888","authenticated-orcid":false,"given":"Trevor","family":"Pugh","sequence":"additional","affiliation":[{"name":"12Genome Sequence Informatics, Ontario Institute for Cancer Research, Toronto, Canada."},{"name":"13Department of Medical Biophysics, University of Toronto, Toronto, Canada."},{"name":"14Princess Margaret Hospital, University Health Network, Toronto, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8396-4515","authenticated-orcid":false,"given":"Shuo Shuo","family":"Liu","sequence":"additional","affiliation":[{"name":"15Department of Statistics and Actuarial Sciences, University of Waterloo, Waterloo, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0347-3888","authenticated-orcid":false,"given":"John M.S.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"10Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Canada."},{"name":"16Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9946-6393","authenticated-orcid":false,"given":"Philip","family":"Awadalla","sequence":"additional","affiliation":[{"name":"2Computational Biology, Ontario Institute for Cancer Research, Toronto, Canada."},{"name":"3Department of Molecular Genetics, University of Toronto, Toronto, Canada."},{"name":"17Dalla Lana School of Public Health, University of Toronto, Toronto, Canada."},{"name":"18Nuffield Department of Population Health, Big Data Institute, University of Oxford, Oxford, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1535-4675","authenticated-orcid":false,"given":"Melanie","family":"Spears","sequence":"additional","affiliation":[{"name":"10Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Canada."},{"name":"19Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6139-0696","authenticated-orcid":false,"given":"Bingshu E.","family":"Chen","sequence":"additional","affiliation":[{"name":"20Canadian Cancer Trials Group, Queen\u2019s University, Kingston, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1699-5888","authenticated-orcid":false,"given":"Jane","family":"Bayani","sequence":"additional","affiliation":[{"name":"10Diagnostic Development, Ontario Institute for Cancer Research, Toronto, Canada."},{"name":"19Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6007-7494","authenticated-orcid":false,"given":"Wendy R.","family":"Parulekar","sequence":"additional","affiliation":[{"name":"20Canadian Cancer Trials Group, Queen\u2019s University, Kingston, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"2025111305535149600_bib1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JOP.777003","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"6","author":"Hammond","year":"2010","journal-title":"J Oncol Pract"},{"key":"2025111305535149600_bib2","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1200\/JCO.2011.38.1095","article-title":"FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer","volume":"30","author":"Bergh","year":"2012","journal-title":"J Clin Oncol"},{"key":"2025111305535149600_bib3","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.2007.13.5822","article-title":"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT","volume":"26","author":"Chia","year":"2008","journal-title":"J Clin Oncol"},{"key":"2025111305535149600_bib4","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1200\/JCO.2002.10.057","article-title":"Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment","volume":"20","author":"Howell","year":"2002","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2025111305535149600_bib5","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.3747\/co.25.4000","article-title":"Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines","volume":"25","author":"Matutino","year":"2018","journal-title":"Curr Oncol"},{"key":"2025111305535149600_bib6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1158\/1078-0432.CCR-11-0509","article-title":"Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4\/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer","volume":"18","author":"Flaherty","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025111305535149600_bib7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025111305535149600_bib8","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"2025111305535149600_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"key":"2025111305535149600_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025111305535149600_bib11","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jnci\/djy109","article-title":"Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for HR+\/HER2\u2212 advanced breast cancer","volume":"111","author":"Di\u00e9ras","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"2025111305535149600_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-020-00771-5","article-title":"Impact of dose reduction on efficacy: implications of exposure-response analysis of palbociclib","volume":"16","author":"Zheng","year":"2021","journal-title":"Target Oncol"},{"key":"2025111305535149600_bib13","doi-asserted-by":"crossref","first-page":"104290","DOI":"10.1016\/j.esmoop.2025.104290","article-title":"Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer","volume":"10","author":"Buijs","year":"2025","journal-title":"ESMO Open"},{"key":"2025111305535149600_bib14","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/jcph.902","article-title":"Characterization of neutropenia in advanced cancer patients following palbociclib treatment using a population pharmacokinetic-pharmacodynamic modeling and simulation approach","volume":"57","author":"Sun","year":"2017","journal-title":"J Clin Pharmacol"},{"key":"2025111305535149600_bib15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025111305535149600_bib16","first-page":"54299","article-title":"Preparation of formalin-fixed paraffin-embedded tissue cores for both RNA and DNA extraction","volume":"114","author":"Patel","year":"2016","journal-title":"J Vis Exp"},{"key":"2025111305535149600_bib17","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"key":"2025111305535149600_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12920-015-0129-6","article-title":"Development and verification of the PAM50-based Prosigna breast cancer gene signature assay","volume":"8","author":"Wallden","year":"2015","journal-title":"BMC Med Genomics"},{"key":"2025111305535149600_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s40425-018-0367-1","article-title":"Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)","volume":"6","author":"Danaher","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025111305535149600_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"key":"2025111305535149600_bib21","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1093\/nar\/gkz474","article-title":"High efficiency error suppression for accurate detection of low-frequency variants","volume":"47","author":"Wang","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2025111305535149600_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"key":"2025111305535149600_bib23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"key":"2025111305535149600_bib24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2017.76.0033","article-title":"Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer","volume":"36","author":"Stover","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"2025111305535149600_bib25","doi-asserted-by":"crossref","first-page":"PD1-10","DOI":"10.1158\/1538-7445.SABCS18-PD1-10","article-title":"Abstract PD1-10: randomized phase II study comparing two different schedules of palbociclib plus second line endocrine therapy in women with estrogen receptor positive, HER2 negative advanced\/metastatic breast cancer: CCTG MA38 (NCT02630693)","volume":"79","author":"Parulekar","year":"2019","journal-title":"Cancer Res"},{"key":"2025111305535149600_bib26","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13073-023-01201-7","article-title":"Longitudinal multi-omics study of palbociclib resistance in HR-positive\/HER2-negative metastatic breast cancer","volume":"15","author":"Park","year":"2023","journal-title":"Genome Med"},{"key":"2025111305535149600_bib27","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/annonc\/mdz037","article-title":"Model-informed drug development approach supporting approval of the 4-week (Q4W) dosing schedule for nivolumab (Opdivo) across multiple indications: a regulatory perspective","volume":"30","author":"Bi","year":"2019","journal-title":"Ann Oncol"},{"key":"2025111305535149600_bib28","doi-asserted-by":"crossref","first-page":"JCO1800045","DOI":"10.1200\/JCO.18.00045","article-title":"Time is money: optimizing the scheduling of nivolumab","volume":"36","author":"Ratain","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025111305535149600_bib29","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41416-021-01415-9","article-title":"Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"125","author":"Burris","year":"2021","journal-title":"Br J Cancer"},{"key":"2025111305535149600_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41523-024-00639-1","article-title":"Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study","volume":"10","author":"Goetz","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"2025111305535149600_bib31","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1002\/onco.13531","article-title":"Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: safety analysis of MONARCH 2 and MONARCH 3","volume":"26","author":"Rugo","year":"2020","journal-title":"Oncologist"},{"key":"2025111305535149600_bib32","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djp082","article-title":"Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer","volume":"101","author":"Cheang","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"2025111305535149600_bib33","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1158\/1078-0432.CCR-13-2943","article-title":"TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance","volume":"20","author":"Silwal-Pandit","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2025111305535149600_bib34","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1158\/0008-5472.CAN-16-2717","article-title":"Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer","volume":"77","author":"Cejalvo","year":"2017","journal-title":"Cancer Res"},{"key":"2025111305535149600_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41523-021-00223-x","article-title":"Immune microenvironment and intrinsic subtyping in hormone receptor-positive\/HER2-negative breast cancer","volume":"7","author":"Griguolo","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"2025111305535149600_bib36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"2025111305535149600_bib37","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment","volume":"9","author":"Garrido-Castro","year":"2019","journal-title":"Cancer Discov"},{"key":"2025111305535149600_bib38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41523-021-00346-1","article-title":"The tale of TILs in breast cancer: a report from The International Immuno-Oncology Biomarker Working Group","volume":"7","author":"El Bairi","year":"2021","journal-title":"NPJ Breast Cancer"},{"key":"2025111305535149600_bib39","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41374-020-00506-0","article-title":"Protein-based immune profiles of basal-like vs. luminal breast cancers","volume":"101","author":"Walens","year":"2021","journal-title":"Lab Invest"},{"key":"2025111305535149600_bib40","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s43018-021-00190-z","article-title":"Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response","volume":"2","author":"McNamara","year":"2021","journal-title":"Nat Cancer"},{"key":"2025111305535149600_bib41","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1093\/annonc\/mdz215","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"30","author":"Hortobagyi","year":"2019","journal-title":"Ann Oncol"},{"key":"2025111305535149600_bib42","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/jnci\/djaa087","article-title":"Circulating tumor DNA markers for early progression on fulvestrant with or without palbociclib in ER+ advanced breast cancer","volume":"113","author":"O\u2019Leary","year":"2021","journal-title":"J Natl Cancer Inst"},{"key":"2025111305535149600_bib43","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1158\/1078-0432.CCR-22-0305","article-title":"Overall survival with palbociclib and fulvestrant in women with HR+\/HER2\u2212 ABC: updated exploratory analyses of PALOMA-3, a double-blind, phase III randomized study","volume":"28","author":"Cristofanilli","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025111305535149600_bib44","doi-asserted-by":"crossref","first-page":"6761","DOI":"10.1038\/s41598-021-86238-7","article-title":"Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients","volume":"11","author":"Muendlein","year":"2021","journal-title":"Sci Rep"},{"key":"2025111305535149600_bib45","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.annonc.2024.09.010","article-title":"Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials","volume":"36","author":"Andr\u00e9","year":"2025","journal-title":"Ann Oncol"},{"key":"2025111305535149600_bib46","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.ccell.2024.10.013","article-title":"Long-term breast cancer response to CDK4\/6 inhibition defined by TP53-mediated geroconversion","volume":"42","author":"Kudo","year":"2024","journal-title":"Cancer Cell"},{"key":"2025111305535149600_bib47","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","article-title":"ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer","volume":"12","author":"Jeselsohn","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"2025111305535149600_bib48","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41467-018-03215-x","article-title":"Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer","volume":"9","author":"O\u2019Leary","year":"2018","journal-title":"Nat Commun"},{"key":"2025111305535149600_bib49","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3390\/cancers15041306","article-title":"CDK4\/6 inhibitors overcome endocrine ESR1 mutation-related resistance in metastatic breast cancer patients","volume":"15","author":"Crucitta","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025111305535149600_bib50","doi-asserted-by":"crossref","first-page":"EVIDoa2300231","DOI":"10.1056\/EVIDoa2300231","article-title":"CDK4\/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer","volume":"3","author":"Lloyd","year":"2024","journal-title":"NEJM Evid"},{"key":"2025111305535149600_bib51","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1200\/JCO.2017.74.8301","article-title":"Tumor PIK3CA genotype and prognosis in early-stage breast cancer: a pooled analysis of individual patient data","volume":"36","author":"Zardavas","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025111305535149600_bib52","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1200\/JCO.2013.53.8272","article-title":"Mutational analysis of PI3K\/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study","volume":"32","author":"Sabine","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025111305535149600_bib53","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-21-3276","article-title":"Clinical significance of PIK3CA and ESR1 mutations in circulating tumor DNA: analysis from the MONARCH 2 study of abemaciclib plus fulvestrant","volume":"28","author":"Tolaney","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025111305535149600_bib54","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"2025111305535149600_bib55","doi-asserted-by":"crossref","first-page":"eabm8729","DOI":"10.1126\/scitranslmed.abm8729","article-title":"Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing","volume":"15","author":"Fairchild","year":"2023","journal-title":"Sci Transl Med"},{"key":"2025111305535149600_bib56","doi-asserted-by":"crossref","first-page":"599","DOI":"10.3390\/cancers14030599","article-title":"PARP inhibitors: a major therapeutic option in endocrine-receptor positive breast cancers","volume":"14","author":"Collet","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025111305535149600_bib57","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s43018-021-00215-7","article-title":"Serial single-cell genomics reveals convergent subclonal evolution of resistance as early-stage breast cancer patients progress on endocrine plus CDK4\/6 therapy","volume":"2","author":"Griffiths","year":"2021","journal-title":"Nat Cancer"},{"key":"2025111305535149600_bib58","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41523-021-00218-8","article-title":"Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4\/6 inhibition and endocrine therapy","volume":"7","author":"Mart\u00ednez-S\u00e1ez","year":"2021","journal-title":"NPJ Breast Cancer"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0346\/3662821\/crc-25-0346.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/11\/1998\/3670421\/crc-25-0346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/5\/11\/1998\/3670421\/crc-25-0346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T10:54:04Z","timestamp":1763031244000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/5\/11\/1998\/767243\/Continuous-versus-Standard-Palbociclib-Treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0346","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.30609183","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609192","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609180","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609231","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609198","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609186","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609195","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609225","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609204","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609216","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609189","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609228","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609210","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609222","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609201","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609234","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609213","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609207","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.30609219","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8145771","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}